ABSTRACT
Background: Pharmacology, the study of drugs, is loaded with thousands of drug names, their mechanism of action, and adverse effects to be memorized, among which the drugs acting on central nervous system, especially antipsychotics, is a night mare for every medical student. “The Storytelling method” is implemented to increase the knowledge of students on antipsychotic drugs using storytelling method as an effective teaching strategy. Aims and Objectives: The aims of this study were to evaluate the effect of reflective writing in learning Pharmacology, among 2nd year MBBS students in the form of storytelling. Materials and Methods: Fifty students from 2nd year MBBS Students were involved in this teaching strategy. Students were randomly divided into ten groups (five per group). They were instructed to frame their own story/case scenario of a psychotic person treated with a P (Personalized) drug of their choice, the specific adverse effect encountered, and the methods to combat it. A time duration of 15 min was given and one person from each group had to narrate their story with voice modulation and hand gestures, for a maximum of 5 min. Results: Validated questionnaire is used for assessing the effectiveness of “storytelling method.” Six of the questions were quantitative and two were qualitative. More than 90% (n = 45) students described the storytelling session as “Creative and Fun filled” when compared to routine classes. Ninety-four percentage (n = 47) of students responded that “Storytelling” session improved their creative thinking on the subject. Conclusion: Storytelling strategy in pharmacology can help students in better understanding of the drug action and their adverse effects than traditional teaching methods.
ABSTRACT
Oliceridine an intravenous opioid approved in 2020 by the Food and Drug Administration (FDA) to treat moderate-to-severe pain. Oliceridin developed with a novel mechanism that is biased agonism toward G-protein-coupled receptors pathway. Being biased agonist, it does not activate beta arrestin pathway responsible for opioid-related adverse events (ORAE), especially respiratory depression. Because of the novel mechanism, oliceridine has paved a pathway to decrease ORAE. Oliceridine has received breakthrough status by FDA. However, FDA denied oliceridine approval and withdrew breakthrough status by 2019. FDA made this decision because of the inadequacy of the safety data. Abuse potential and QT prolongation studies are conducted as per FDA recommendation in the year 2019; oliceridine was approved for moderate to severe pain in adults. This review will briefly summarize the pharmacological properties and study results of oliceridine in the management of pain. Thorough literature search was done for the efficacy and safety of oliceridine, search was done in electronic database of PubMed and Cochrane from inception till June 2021. Oliceridine was found to be effective in acute severe pain with less OREA when compared to morphine. Oliceridine has many drawbacks than what is hypothesized earlier, but this approach has opened new options for patients suffering from severe pain. Long?term effect of oliceridine has to be monitored to assess the effects of biased agonism.